Home Page

NEW YORK, Aug. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0946319/Addison's-Disease-Primary-or-Chronic-Adrenal-Insufficiency-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, the industry analysis specialist, has released its new report, "Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Addison's Disease Therapeutics market. The report identifies the key trends shaping and driving the global Addison's Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Addison's Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Scope

The report provides information on the key drivers and challenges of the Addison's Disease Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Addison's Disease Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Addison's Disease Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Addison's Disease Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Addison's Disease Therapeutics market

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Addison's Disease Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Addison's Disease Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Addison's Disease Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 5

2 Addison's Disease Therapeutics - Introduction 6

2.1 Disease Overview 6

2.1.1 Types of Adrenal Insufficiency 6

2.2 Epidemiology 8

2.3 Etiology 8

2.3.1 Autoimmune Disorders 8

2.3.2 Tuberculosis 8

2.3.3 Other Causes 8

2.4 Pathophysiology 9

2.5 Symptoms and Clinical Signs 9

2.6 Commonly Used Diagnostic Tests 10

2.7 Treatment and Management Options for Addison's Disease 10

2.7.1 Types of Glucocorticoid Drugs and their Doses 10

2.8 GlobalData Pipeline Report Guidance 11

3 Addison's Disease Therapeutics - Market Characterization 12

3.1 Addison's Disease Therapeutics Market Size (2006-2011) - Global 12

3.2 Addison's Disease Therapeutics Market Forecast (2011-2019) - Global 13

3.3 Addison's Disease Therapeutics Market Size (2006-2011) - The US 14

3.4 Addison's Disease Therapeutics Market Forecast (2011-2019) - The US 15

3.5 Addison's Disease Therapeutics Market Size (2006-2011) - France 16

3.6 Addison's Disease Therapeutics Market Forecast (2011-2019) - France 17

3.7 Addison's Disease Therapeutics Market Size (2006-2011) - Germany 18

3.8 Addison's Disease Therapeutics Market Forecast (2011-2019) - Germany 19

3.9 Addison's Disease Therapeutics Market Size (2006-2011) - Italy 20

3.10 Addison's Disease Therapeutics Market Forecast (2011-2019) - Italy 21

3.11 Addison's Disease Therapeutics Market Size (2006-2011) - Spain 22

3.12 Addison's Disease Therapeutics Market Forecast (2011-2019) - Spain 23

3.13 Addison's Disease Therapeutics Market Size (2006-2011) - The UK 24

3.14 Addison's Disease Therapeutics Market Forecast (2011-2019) - The UK 25

3.15 Addison's Disease Therapeutics Market Size (2006-2011) - Japan 26

3.16 Addison's Disease Therapeutics Market Forecast (2011-2019) - Japan 27

3.17 Drivers and Barriers for the Addison's Disease Therapeutics Market 28

3.17.1 Drivers for the Addison's Disease Therapeutics Market 28

3.17.2 Barriers to the Addison's Disease Therapeutics Market 28

3.18 Opportunity and Unmet Need Analysis 29

3.19 Key Takeaway 30

4 Addison's Disease Therapeutics - Competitive Assessment 31

4.1 Overview 31

4.2 Strategic Competitor Assessment 31

4.3 Product Profiles for the Marketed Products in the Addison's Disease Therapeutics Market 32

4.3.1 Glucocorticoid Replacement Therapy 32

4.3.2 Mineralocorticoid Replacement Therapy 33

4.4 Key Takeaway 33

5 Addison's Disease Therapeutics - Pipeline Assessment 34

5.1 Overview 34

5.2 Strategic Pipeline Assessment 34

5.2.1 Addison's Disease Therapeutics - Phase I Clinical Pipeline 34

5.3 Technology Trends Analytic Framework 34

5.4 Recently Approved Pipeline Product 35

5.4.1 Plenadren (hydrocortisone) 35

5.5 Key Takeaway 36

6 Addison's Disease Therapeutics - Clinical Trials Mapping 37

6.1 Clinical Trials by Region and Country 37

6.2 Clinical Trials by Phase 38

6.3 Clinical Trials by Trial Status 38

6.4 Clinical Trials Mapping by Sponsors 39

7 Addison's Disease Therapeutics - Strategic Assessment 40

7.1 Key Events Impacting the Future Market 40

7.2 Addison's Disease Therapeutics - Implications for Future Market Competition 41

8 Addison's Disease Therapeutics Market - Future Players 42

8.1 Introduction 42

8.2 Company Profiles 42

8.2.1 DuoCort Pharma AB 42

8.2.2 ViroPharma 43

9 Addison's Disease Therapeutics - Licensing and Partnership Deals 44

10 Addison's Disease Therapeutics - Appendix 45

10.1 Market Definitions 45

10.2 Acronyms 45

10.3 Research Methodology 45

10.3.1 Coverage 45

10.3.2 Secondary Research 46

10.3.3 Forecasting 46

10.3.4 Primary Research 49

10.3.5 Expert Panel Validation 49

10.4 Contact Us 49

10.5 Disclaimer 49

10.6 Bibliography 50

1.1 List of Tables

Table 1: Addison's Disease Prevalence in Seven Major Markets 8

Table 2: Signs and Symptoms of Adrenal Insufficiency 9

Table 3: Most Commonly Glucocorticoid Drugs and Doses 10

Table 4: Addison's Disease Therapeutics Market, Global, Revenue ($m), 2006-2011 12

Table 5: Addison's Disease Therapeutics Market, Global, Forecast ($m), 2011-2019 13

Table 6: Addison's Disease Therapeutics Market, The US, Revenue ($m), 2006-2011 14

Table 7: Addison's Disease Therapeutics Market, The US, Forecasts ($m), 2011-2019 15

Table 8: Addison's Disease Therapeutics Market, France, Revenue ($m), 2006-2011 16

Table 9: Addison's Disease Therapeutics Market, France, Forecasts ($m), 2011-2019 17

Table 10: Addison's Disease Therapeutics Market, Germany, Revenue ($m), 2006-2011 18

Table 11: Addison's Disease Therapeutics Market, Germany, Forecasts ($m), 2011-2019 19

Table 12: Addison's Disease Therapeutics Market, Italy, Revenue ($m), 2006-2011 20

Table 13: Addison's Disease Therapeutics Market, Italy, Forecasts ($m), 2011-2019 21

Table 14: Addison's Disease Therapeutics Market, Spain, Revenue ($m), 2006-2011 22

Table 15: Addison's Disease Therapeutics Market, Spain, Forecasts ($m), 2011-2019 23

Table 16: Addison's Disease Therapeutics Market, The UK, Revenue ($m), 2006-2011 24

Table 17: Addison's Disease Therapeutics Market, The UK, Forecasts ($m), 2011-2019 25

Table 18: Addison's Disease Therapeutics Market, Japan, Revenue ($m), 2006-2011 26

Table 19: Addison's Disease Therapeutics Market, Japan, Forecasts ($m), 2011-2019 27

Table 20: Addison's Disease Therapeutics-Phase I Pipeline, 2011 34

Table 21: Addison's Disease Therapeutics - Clinical Trials by Country, 2011 37

Table 22: Addison's Disease Therapeutics - Clinical Trials by Phase, 2011 38

Table 23: Addison's Disease Therapeutics - Clinical Trials by Status, 2011 38

Table 24: Addison's Disease Therapeutics - Overall Sponsors, 2011 39

Table 25: Addison's Disease Therapeutics Market - Clinical Pipeline by Company, 2011 42

Table 26: Addison's Disease - Global, Deals, 2011 44

1.2 List of Figures

Figure 1: Adrenal Hormones Regulation 7

Figure 2: Addison's Disease Therapeutics Market, Global, Revenue ($m), 2006-2011 12

Figure 3: Addison's Disease Therapeutics Market, Global, Forecast ($m), 2011-2019 13

Figure 4: Addison's Disease Therapeutics Market, The US, Forecast ($m), 2006-2011 14

Figure 5: Addison's Disease Therapeutics Market, The US, Forecasts ($m), 2011-2019 15

Figure 6: Addison's Disease Therapeutics Market, France, Revenue ($m), 2006-2011 16

Figure 7: Addison's Disease Therapeutics Market, France, Forecast ($m), 2011-2019 17

Figure 8: Addison's Disease Therapeutics Market, Germany, Revenue ($m), 2006-2011 18

Figure 9: Addison's Disease Therapeutics Market, Germany, Forecast ($m), 2011-2019 19

Figure 10: Addison's Disease Therapeutics Market, Italy, Revenue ($m), 2006-2011 20

Figure 11: Addison's Disease Therapeutics Market, Italy, Forecast ($m), 2011-2019 21

Figure 12: Addison's Disease Therapeutics Market, Spain, Revenue ($m), 2006-2011 22

Figure 13: Addison's Disease Therapeutics Market, Spain, Forecast ($m), 2011-2019 23

Figure 14: Addison's Disease Therapeutics Market, The UK, Revenue ($m), 2006-2011 24

Figure 15: Addison's Disease Therapeutics Market, The UK, Forecast ($m), 2011-2019 25

Figure 16: Addison's Disease Therapeutics Market, Japan, Revenue ($m), 2006-2011 26

Figure 17: Addison's Disease Therapeutics Market, Japan, Forecasts ($m), 2011-2019 27

Figure 18: Opportunity and Unmet Need in the Addison's Disease Therapeutics Market 30

Figure 19: Addison's Disease Therapeutics - Strategic Competitor Assessment, 2011 31

Figure 20: Addison's Disease Therapeutics - Technology Trends Analytics Framework, 2011 34

Figure 21: Addison's Disease Therapeutics - Technology Trends Analytics Framework - Description, 2011 35

Figure 22: Addison's Disease Therapeutics - Clinical Trials by Country, 2011 37

Figure 23: Addison's Disease Therapeutics - Clinical Trials by Phase, 2011 38

Figure 24: Addison's Disease Therapeutics - Overall Sponsors, 2011 39

Figure 25: Addison's Disease Therapeutics Market, Drivers and Barriers, 2011 40

Figure 26: Implications for Future Market Competition in the Addison's Disease Therapeutics Market, 2011 41

Figure 27: GlobalData Market Forecasting Model 48

DuoCort Pharma AB

ViroPharma

More  

Check our  

Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker